Work

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)

Year: 2006
Type: article
Abstract: This summary document is an update to the full British HIV Association (BHIVA) Treatment Guidelines published in HIV Medicine in July 2005 (Volume 6, Supplement 2). Only the 'What to start with' and 'Treatment-experienced patients' sections have been completely rewritten. The tables of recommendations (Tables 1–7) have also been updated to include new data. Please refer to the full guidelines for more information. Since the last version of these guidelines there have been few new data relating to adherence to medication in general, or to highly active antiretroviral therapy (HAART) in particular. Studies continue to support a role for brief interventions including treatment-related education and individualized adherence problem-solving in increasing adherence (at least over the following months) [1,2]. A study looking at using long-term partners to support adherence showed a marked beneficial effect on adherence in the short term, but this was not sustained at 6 months [3]. In the Gilead 934 study, although adherence (measured by pill count) was statistically significantly higher in the once-daily arm vs. twice-daily, the clinical difference was small (3%) and may have arisen because of the poorer tolerability of the twice-daily arm rather than because of any benefit of once-daily dosing [4]. Research in the USA examined the costs in real terms of delivering a variety of adherence interventions over the first year of patient support. The majority of interventions were delivered by nurses. Median direct annual cost was $420 (range $60–700) per patient; 66% of this was attributed to staffing but this also included $72 per annum for patient incentives, which are unlikely to be deployed in the UK. Although it is difficult to extrapolate these costs to NHS services in the UK, the absolute cost of adherence interventions appears to be relatively low, and slightly less than that of a genotype resistance test [5]. No new data have emerged in the past year to change the view of the Committee that, if antiretroviral therapy is started in the context of primary HIV infection, it should normally only be in the setting of a clinical trial (e.g. the MRC SPARTAC study [6]). Decisions on when to start treatment are based on an assessment of the risk of disease progression over the medium term if treatment is not started (e.g. using data from the CASCADE collaboration [7]), vs. the potential risks of starting treatment earlier (toxicity and resistance). The risk of disease progression is determined largely by the CD4 cell count, plasma viral load and the age of the patient. No new data have emerged since the previous guidelines to alter the Committee's view that treatment should start before the CD4 cell count has fallen to below 200 cells/μL. This is because of the higher risk of death or disease progression in patients who delay starting treatment until their CD4 cell count has fallen to this level, and the reduced efficacy of HAART when introduced at a count of <200 cells/μL in some studies. The implication of this is that earlier diagnosis of infection remains paramount; this is only likely to be achieved by much more widespread and normalized use of HIV antibody testing [8]. In patients with counts above this level, the risk of disease progression without therapy should be considered. Therapy should be started if the patient wishes to start, the medium-term risk of disease progression is high (e.g.>2–4% in 6 months) and the likelihood of harm as a result of drug toxicity or the selection of resistant virus is considered to be low. This is likely to mean that the majority of patients with CD4 counts >350 cells/μL should continue to defer treatment. Although cohort studies [9–11] have consistently shown that the risk of disease progression in this group tends to be lower for up to several years if therapy is started earlier, this is at the cost of significant drug toxicity, necessitating drug switching or stopping therapy in a significant minority [9], and the absolute risk of disease progression in this group remains very low. Other cohort studies (albeit in patient groups using regimens that might not be recommended currently [12,13]) have demonstrated that selection of drug-resistant virus occurs in 25% of patients after 2–3 years, suggesting that deferral of initiation may preserve future treatment options. Patients randomized to the drug conservation (DC) arm (i.e. intermittent therapy) of the SMART study [14] had a significantly increased risk of opportunistic infection or death after 16 months of follow up compared to those in the virological suppression (VS) arm (i.e. continuous therapy). Importantly, this benefit was seen across all CD4 cell count strata, not only in those with a nadir CD4 count of <350 cells/μL. These data have been interpreted as evidence that drug treatment should be started at an earlier stage than is currently the case. However, analyses of the relative rates of disease progression in the two arms indicate that the absolute risk of disease progression remains relatively low in the DC arm of the study (approximately 2% per year compared to 1% in the VS arm). This is consistent with existing data from cohort studies, and as such does not provide convincing evidence to change the recommendations of the 2005 guidelines. Rather, this reinforces the evidence that there is a continuous increase in the risk of disease progression and death in untreated patients as the CD4 cell count falls, and that decisions on starting therapy need to be individualized, taking into account the specific circumstances and risks present in each patient. Patients in the DC arm were also found to have much higher rates of cardiovascular, renal and hepatic disease than were seen in the VS arm. If this phenomenon is attributable to the effect of untreated HIV infection, this would be a further argument for earlier therapy. As the tolerability and toxicity profiles of initial therapy improve and the risk of selecting resistant virus with initial therapy falls [15], it will increasingly become reasonable to consider starting therapy earlier than previously (i.e. earlier in the CD4 count range 200–350 cells/μL, and above counts of 350 cells/μL in selected patients, such as older patients, those with higher viral load, and those with other comorbidities such as hepatitis B or C virus infection). There is overwhelming evidence from cohort studies that the very dramatic fall in AIDS-related mortality and frequency of AIDS events seen in the developed world over the last 10 years coincides with the introduction of HAART. Further improvements in treatment have led to fewer naïve patients now failing first-line therapy. Measurement of the success of a regimen is achieving a viral load of <50 HIV-1 RNA copies/mL within 3–6 months of starting therapy and then maintaining this thereafter. Regardless of the baseline viral load, a level of 1000 copies/mL has been found to be achievable in the majority of people by 4 weeks from start of therapy. Failure to achieve this is strongly associated with failure to reach viral load below 50 copies/mL within 24 weeks. A viral load above 1000 copies/mL measured 4 weeks after the initiation of therapy therefore should prompt questions over possible poor adherence or other reasons such as reduced drug levels or primary drug resistance. HAART regimens should be individualized in order to achieve the best potency, adherence and tolerability; to minimize potential long-term toxicity and to avoid any likely drug–drug interactions. The cost of the regimen should also be considered. Previous guidelines have been hampered by the paucity of published data to definitively inform whether HAART based around a non-nucleoside reverse transcriptase inhibitor (NNRTI) or boosted protease inhibitor (PI) regimen is preferable. Moreover, there have been only limited data on comparative efficacy among boosted PIs. Studies have shown the superiority of efavirenz (EFV)-containing regimens over nelfinavir (NFV)-, boosted saquinavir (SQV)- and boosted amprenavir-containing regimens [16–18]. A recently presented controlled trial comparing a currently recommended boosted PI [ritonavir-boosted lopinavir (LPV/r)] with EFV in naïve patients has demonstrated on intention-to-treat (ITT) analysis the superiority of an EFV-based HAART regimen over 96 weeks [19]. This resulted from a lower rate of virological failure in the EFV arm, with no significant difference between the arms in treatment-limiting toxicity. Less class-emergent resistance and improved immunological response was, however, seen in the boosted LPV arm. In addition, a 48-week study comparing LPV/r with ritonavir-boosted fosamprenavir (FOS/r) has demonstrated the noninferiority of twice-daily FOS/r at all CD4 cell count and viral load strata [20]. It is important to select the regimen best suited to the individual patient, and therefore to fully assess baseline risk factors for resistance, hepatitis B/hepatitis C virus coinfection, cardiovascular disease, diabetes, and psychiatric disease. In addition, lifestyle issues including smoking, obesity, alcohol use, and recreational drug use should be taken into account, as well as gender and the potential for pregnancy. The advantages and disadvantages in terms of potency, convenience, toxicity, salvageability and potential drug–drug interactions are discussed below. In view of these recently presented data, the Committee recommends that EFV-based HAART should ordinarily be the first-line choice for naïve patients. However, it must be emphasized that any drug combination must be tailored to the patient and, in many instances, including primary reverse transcriptase resistance, a boosted PI is preferable. This therefore remains a recommended alternative option. With a second wave of drugs within the PI and NNRTI classes as well as novel target classes currently in Phase III/IV studies, we believe that patients should continue to be informed about and encouraged to participate in available clinical trials to further answer these questions. NNRTI-based regimens have now been extensively studied with good durability data available for EFV beyond 3 years [21,22]. They have the advantages of convenience and lack of long-term toxicity and EFV is the preferred NNRTI for initial therapy. However, EFV is not a drug that is well tolerated by all patients and the side-effect profile needs to be carefully explained to each patient before starting therapy. Three per cent of patients may experience extreme disorientation including paranoia, nightmares and suicidal ideation, and discontinuation rates of 10–20% have been reported over time in clinical practice. Nevirapine (NVP) is the alternative NNRTI but is associated with a worse toxicity profile. In many randomized controlled trials, EFV has demonstrated improved virological efficacy when compared to other treatment regimens including PI-, boosted PI-, NVP- and 3NRTI-based regimens. In the 2NN study [23,24], data were obtained to compare EFV and NVP in a randomized manner and showed that they were comparable in potency. Equivalence was not formally proven, with a small chance that NVP was superior to EFV and a greater chance of the reverse. However, the principal reason for the recommendation of EFV as the preferred NNRTI is related to toxicity in the NVP arm. The major limitation of EFV, as for all currently available NNRTIs, is the low genetic barrier to resistance. This is becoming a major concern because of the continuing and, in some countries/groups, increasing incidence of primary resistance. A single mutation is sufficient to confer resistance to EFV (leading to the loss of currently licensed drugs in this class in future regimens), although not to the second-generation NNRTIs currently under evaluation in Phase III/IV studies. NNRTI resistance is also almost always accompanied by the emergence of nucleoside mutations, limiting options for this class as well. The major side effect of EFV is dysphoria, which needs to be discussed in detail with the patient prior to commencing the drug. Manifestations include vivid dreams and/or nightmares, sleep and mood disturbance, drowsiness and disorientation. Most are mild–moderate and self-limiting and can be managed with a short course of hypnotics: it is unusual for patients to discontinue the drug for this reason within trials. Nevertheless, in a small minority, symptoms persist and may be severe enough to warrant switching to an alternative agent. The evidence is conflicting as to whether or not side effects are more common in individuals with a previous psychiatric disturbance [25]. Rashes do occur, but severe rashes with EFV are unusual (the incidence of Stevens–Johnson syndrome is 0.1%). Similarly, hypersensitivity hepatitis occurs (3.4% in the 2NN study) but fulminant hepatitis is exceptionally rare. Lipid abnormalities, mainly rises above baseline values in total and low-density lipoprotein (LDL) cholesterol, are not infrequently observed in patients on EFV-containing combinations [23]. EFV may be teratogenic and there have been four retrospective reports of neural tube defects in mothers taking EFV in the first trimester. Such defects have not been described in prospectively collected data and the relative risk of its use in early pregnancy remains uncertain [26]. Nevertheless, women of childbearing age should be warned about becoming pregnant whilst on EFV and, wherever possible, it should be avoided in women who may contemplate pregnancy. EFV has a long half-life when compared with nucleosides and it is important to maintain viral suppression for a period after discontinuation to prevent functional monotherapy and the emergence of resistance. This can be achieved by either continuing the nucleosides or substitution of a boosted PI. The optimal duration of staggered discontinuation is undetermined but is longer in certain ethnic groups and may range from 1 to 3 weeks. As discussed above, NVP has been compared with EFV in the 2NN study and has been shown to be of comparable potency. In this study, however, there was more serious toxicity in the NVP arm, with two drug-related deaths, one from liver failure and one from methicillin-resistant Staphylococcus aureus septicaemia in a patient with Stevens–Johnson syndrome. The major side effects are rash and hepatitis. The rash is usually mild and self-limiting but may occasionally manifest as Stevens–Johnson syndrome (incidence 0.3%) with rare fatalities. The rash is not reduced by the coadministration of steroids, which should be avoided [27]. Hepatitis is an infrequent side effect that occurs in the first 6 weeks of therapy but fulminant liver failure and deaths have been reported. Recent analyses have shown a 12-fold higher incidence of symptomatic hepatic events in women with CD4 counts >250 cells/μL (11% vs. 0.9%) and a 6-fold higher incidence in men with CD4 counts >400 cells/μL (8% vs. 1.2%) and this drug should be avoided in these patients, as well as those with active hepatitis B or C virus infection or patients with elevated liver function tests at baseline. NVP is currently used twice a day, but the pharmacokinetics and now clinical trial data indicate that once-daily dosing is possible, although this leads to more abnormalities of liver function [23]. Based on these data, NVP is not now recommended as a preferred regimen in patients starting HAART, but should be used in patients in whom other regimens would have disadvantages (e.g. women desiring to become pregnant and possibly those with a previous psychiatric history) and only within the CD4 cell count recommendations. It remains a well-tolerated drug with no adverse effect on lipids, and, when used within the restrictions above, the risk of hepatotoxicity is probably extremely low. There are also cost benefits of NVP over EFV. A 14-day lead-in period of 200 mg daily should be prescribed before increasing to twice-daily dosing unless switching directly from EFV. The same recommendations apply when discontinuing NVP as apply for EFV. Delavirdine is currently unlicensed in the UK and is not recommended. The dramatic decline in clinical progression and HIV-related deaths followed the introduction of the PI class of antiretrovirals. These agents have shown clinical and surrogate marker efficacy in clinical practice, with a possible enhanced rise in CD4 cell count over NNRTIs in naïve patients. Sustained suppression of plasma HIV-1 RNA levels has been observed with more than 7 years of continued immunological recovery in patients treated with a boosted PI. There is now enough data to recommend that if a PI is chosen as part of an initial HAART regimen then, with few exceptions, this should be a boosted agent. This is because ritonavir (RTV) boosting increases drug exposure and prolongs the drug half-life, thereby reducing pill burden and dosing frequency, and optimizing adherence. It also limits the development of resistance. The disadvantage of this approach is a possible risk of greater lipid abnormalities, particularly raised fasting triglycerides. In randomized studies, the development of resistance in patients failing therapy has been shown to be higher in those starting with NNRTI or unboosted PI regimens compared with those starting with boosted PIs [28,29]. This was evident in the class comparison study between boosted LPV and EFV where, of those viruses sequenced in patients with virological failure, NNRTI and primary PI mutations were 48% and 4%, respectively, with NRTI mutations being twice as frequent in the NNRTI arm (33 vs. 15%) [19]. The Committee recommends LPV/r or FOS/r dosed twice daily as the preferred regimens, with alternatives to include boosted SQV (hard gel capsule or film-coated capsule) or boosted atazanavir (ATZ). Data from the original licensing study [30] showed superior surrogate marker endpoint for patients using LPV/r when compared to NFV, with lower numbers of patients discontinuing for side effects. Additionally, patients randomized to LPV/r who developed virological failure had no evidence of PI resistance. The main side effects of this regimen are lipid abnormalities and gastrointestinal side effects, with diarrhoea being the predominant symptom. The new formulation of LPV/r tablet is now available with lower pill burden, no food requirement and less interpatient pharmacokinetic variability, and does not need refrigeration. Boosted FOS has been compared as once-daily dosed 1400 mg/200 mg to NFV (SOLO) and as twice-daily dosed 700 mg/100 mg to boosted LPV (KLEAN) in clinical studies in naïve patients [20,31]. Against NFV, there was no overall difference in the surrogate marker endpoint of <400 copies/mL (69% in the FOS/r arm vs. 68% in the NFV although significantly more patients with viral copies/mL and randomized to fosamprenavir achieved viral load from the study FOS/r to be to LPV/r of those randomized to FOS/r and of those randomized to LPV/r had viral <50 copies/mL at weeks on failure was low in the FOS arm vs. in the LPV and no major PI mutations were Data from the study have also demonstrated that boosted FOS to weeks in naïve patients with only one of PI resistance reported to This regimen has a low pill burden and with the same tolerability and level of as boosted It is licensed in the UK to be dosed twice Boosted SQV has demonstrated in and twice-daily It has been compared as a twice-daily to and LPV/r of patients were the primary endpoint of time to virological failure, LPV/r was superior to and was superior to With the of the mg film-coated SQV has a relatively low pill burden twice and a well-tolerated alternative to LPV in naïve patients, with possibly less gastrointestinal toxicity. lipid abnormalities may a potential long-term toxicity The once-daily is not licensed in the UK and should be used twice This may change the of clinical trials. has been shown to have efficacy to NFV and EFV in clinical studies A study comparing boosted and unboosted demonstrated no difference on analysis at although there were more virological in the unboosted arm has also been shown to have efficacy to LPV/r in patients. The main advantages of are that the drug is dosed daily and has fewer adverse effects on than other boosted PI regimens. main side effect is with or without but this is not associated with liver and in the need to discontinue treatment. It is not licensed in the UK for naïve patients. A disadvantage is the of with This is not by and alternative agents be atazanavir should be The Committee that use of this drug should be boosted in naïve patients and to those with cardiovascular risk factors and a PI is This may change the of clinical trials. There is now surrogate marker endpoint data suggesting that usually as is less than the combination of two with either an NNRTI or a PI. In the arm was less than the other two arms or This was found at high and low viral The Committee now that should only be considered as a starting regimen in very for informed patient choice based on likely poor adherence if alternative options are or medication such as for regimens or should not be used because of high rates of virological failure no regimen can be recommended. However, data that with or without is a possible when a or NNRTI-based HAART be an of HAART with either an NNRTI or an PI. There is no evidence that a NRTI benefits and combinations are associated with more because of toxicity and resistance. There are now NRTI been and four NRTI The of two new combinations and in to has led to the majority of patients who are naïve to being prescribed one of these as their With increasing on convenience, of long-term toxicity, and there are and of each which are discussed below. drug resistance will also the choice of NRTI although currently there is no increase in the UK in the rate of NRTI mutations in recently patients. as is the studied of the NRTI and until been the combination in the UK with EFV, it has virological efficacy to at weeks However, in the Gilead 934 study, was compared with dosed with EFV as the agent. demonstrated a significantly higher frequency of patients with virological greater than copies/mL vs. and adverse events to discontinuation in the arm vs. In this study and the Gilead study with either or dosed with EFV showed high and virological with good tolerability and long-term toxicity. is the and has been shown to virological In studies the drug was either EFV or a boosted the of patients who was at weeks and the individual have been shown to be with the combinations CD4 cell counts at weeks have been demonstrated with and when compared to NRTI combinations well Most experience is of twice-daily However, because of the increasing evidence longer term use with the Committee it is to carefully for this in patients who possibly with with a to an alternative NRTI as as there is any or of its with either or has a profile than including less of reports of renal and an between related and concern has been raised about possible long-term renal toxicity with studies, including clinical and data, have serious renal toxicity in of patients, a rate no to that observed with However, other studies have demonstrated a small but significant in renal function over time when compared to other nucleosides It is that should be used in patients who or are at risk of renal disease, including those Moreover, and should be prior to with treatment. However, in this the Committee that is a and using as first-line the mutation has been observed in a minority of patients In the Gilead study, this mutation in at weeks virological failure rate This was mainly observed in those with CD4 counts of <50 cells/μL and viral has not been observed in patients with virus when to weeks and to 96 weeks The of this mutation and will also be by the drug choice or boosted is well tolerated but a hypersensitivity may in the first 6 weeks from drug and all patients need It has been in of studies and is of dosing These studies used a was also reported in of patients in a study) and the summary of an rate of analysis has a between and of the class 1 which to a the in of this has a high for in The use of this test in clinical has been shown to significantly the rate of from to although its remains to be in a randomized clinical trial and in many are now and in patients with the Although of significant benefit in reducing the likelihood of the Committee that there are only limited and data on its use in clinical and that the remains with patient and There is no evidence of longer term toxicity with to although is greater than with The mutation is seen in at weeks in patients on or a boosted PI virological failure rate and mutations can to in choice of NRTI drugs if they In these NRTI good efficacy and can all be recommended. with EFV, leads to fewer than a difference mainly by toxicity in the first 24 weeks. with long-term is also an important in choice of of is likely to increase with for but a test does not the of and the need for and for for long-term toxicity and resistance development with all combinations is particularly for and experience is limited by comparison to The relative costs of the individual is becoming an increasingly important in treatment in naïve these are in
Source: HIV Medicine
Authors: B Gazzard, A J Bernard, M Boffito, D Churchill, S Edwards, N Fisher, A M Geretti, M Johnson, C Leen, B Peters, A Pozniak, J Ross, J Walsh, E Wilkins, M Youle
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4251271298
FWCI: 26.3
Cites: 56
Cited by: 203
Related to: 10